Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Tricida, Inc.

NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) – Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of individuals and organizations between September 4, 2019 and purchased or otherwise acquired securities of Tricida, Inc. (“Tricida” or the “Company”) (NASDAQ: TCDA) on October 28, 2020 (including the “Class Period”).

All investors who bought shares of Tricida, Inc. and any losses incurred are requested to contact the company immediately classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You can get additional information about the promotion or Join the case on our website, www.whafh.com.

If you suffered a loss in Tricida, Inc. stock. You may, no later than March 8, 2021, request that the court appoint you as the lead plaintiff in the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Tricida, Inc. stock.


Tricida’s drug candidate Veverimer is a polymer being developed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (“CKD”). The company has completed a phase 3 double-blind, placebo-controlled study of Veverimer in patients with CKD and metabolic acidosis.

On September 4, 2019, Tricida announced that it had filed a new Accelerated Approval Program for Veverimer for the treatment of metabolic acidosis in patients with the US Food and Drug Administration (FDA) with CKD.

On July 15, 2020, Tricida announced that it had received a notice from the FDA[ying] Deficiencies that preclude discussion of the labeling and post marketing requirements / obligations at this point. “The company stated:”[t]The notification does not indicate the defects identified by the FDA. “

In that news, the company’s stock price fell $ 10.56, or 40.31%, to close at $ 15.64 per share on July 16, 2020.

Then, on October 29, 2020, after meeting the FDA at the end of the Type A review, Tricida announced that it “now believes the FDA also has evidence of the effect of veverimer on CKD progression from a short-term interim analysis VALOR-CKD for approval under the Accelerated Approval Program and the FDA is unlikely to rely solely on serum bicarbonate data to determine efficacy. “Tricida also announced that it will” significantly reduce its workforce from 152 to 59 people and discuss its commitments with vendors and contract service providers to potentially allow additional financial flexibility. “

In that news, the company’s stock price fell $ 3.90, or 47.16%, to close at $ 4.37 per share on October 29, 2020.

Wolf Haldenstein has extensive experience prosecuting class and derivative disputes in state and federal courts and appeals courts across the country. The firm has lawyers in various fields of activity; and offices in New York, Chicago and San Diego. This law firm’s reputation and expertise in shareholder and other class disputes has been recognized repeatedly by the courts who have appointed them to key positions in complex securities multiple district and consolidated litigation.

If you would like to discuss this campaign or if you have any questions about your rights and interests in this case, please contact Wolf Haldenstein immediately by telephone at (800) 575-0735, by email at classmember@whafh.com or visit our website on www.whafh.com.


Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, director of case and financial analysis
Email: gstone@whafh.com, kcooper@whafh.com, or classmember@whafh.com

Tel .: (800) 575-0735 or (212) 545-4774

This press release may be viewed as a solicitor advertisement in some jurisdictions under applicable laws and ethical rules.

Comments are closed.